Company profile
SERES THERAPEUTICS, INC.
NASDAQ:MCRBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SER-287 | phase2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04995653 | phase1 | completed | 2021-11-24 | 2024-07-23 | Seres Therapeutics, Inc. | A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT |
| NCT03759041 | phase2 | terminated | 2018-12-19 | 2021-05-28 | Seres Therapeutics, Inc. | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis |
| NCT02618187 | phase1 | completed | 2016-01-13 | 2017-12-06 | Seres Therapeutics, Inc. | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis |
| NCT03183128 | phase3 | completed | 2017-07-10 | 2020-07-03 | Seres Therapeutics, Inc. | ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection |
| NCT03183141 | phase3 | completed | 2017-10-23 | 2022-04-29 | Seres Therapeutics, Inc. | ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection |
FDA applications (0)
No records yet.